Search clinical trials for: coagulation-related factors

Total 31769 results

Shandong Provincial Hospital

Recruiting

Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study (MA)

Gastric Cancer Stage | Lymph Node Metastasis

China
Institute of Liver and Biliary Sciences, India

Recruiting

To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients

Liver Cirrhosis | Acute on Chronic Liver Failure

India
Tulane University
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Building Engagement Using Financial Incentives Trial - Hypertension (BENEFIT-H)

Hypertension | Patient Engagement | Health Behavior | Adherence, Patient | Healthcare Patient Acceptance
Catalyst Biosciences

Completed

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Hemophilia B

South Africa
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

Hemophilia B
Bio Products Laboratory

Completed

A Study Investigating Treatment Factor X in People With Factor X Deficiency

Factor X Deficiency

United States, Turkey, Germany, Spain, United Kingdom
Pfizer

Completed

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B

United States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
Laboratoire français de Fractionnement et de Biotechnologies

No longer available

HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency (EAP)

Surgery | Postpartum Hemorrhage | Wound; Rupture, Surgery, Cesarean Section

United States
Grifols Biologicals, LLC

Completed

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Hemophilia B

Bulgaria
Pfizer

Completed

Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

Hemophilia B

Korea, Republic of
Eio Biomedical Ltd.

Completed

Evaluation of the Feasibility, Safety, Initial Efficacy and Clinical Usability of FuseX Anti-Adhesion System

Reduction of Postoperative Adhesions

Lithuania
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

vonWillebrand's Disease

Israel
Masaryk Hospital Krajská zdravotní a.s.

Completed

Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma

Coagulation Disorder | Multiple Trauma | Coagulation Defect; Acquired | Coagulation Factor Deficiency

Czechia
Second Affiliated Hospital, School of Medicine,...

Recruiting

Inflammation and Coagulation Factors for Predicting Cerebral Edema After SAH

Inflammation | Cerebral Edema | Coagulation and Hemorrhagic Disorders

China
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
University of Cagliari
University of Foggia

Completed

Impact on Ovarian Reserve of Diode Laser vs Bipolar Coagulation of Endometriomas

Ovarian Endometrioma

Italy
Central Hospital, Nancy, France

Completed

Risk Factors of Necrotizing Enterocolitis in Premature Newborns (ECUNancyLyon)

Risk Factors | Necrotizing Enterocolitis of Newborn

France
Medical College of Wisconsin

Recruiting

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Hemophilia A

United States
Peking University First Hospital

Not yet recruiting

Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II

Bleeding | Pharmacodynamics | Apixaban | Pharmacogenomics | Biomarker | Ticagrelor | Rivaroxaban | Novel Oral Anticoagulants | NOACs | Dabigatran | Edoxaban | RNA Profile

China
Laboratoire français de Fractionnement et de Biotechnologies

Recruiting

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM (SCOPE HIM)

Hemophilia

United States, Thailand, Malaysia, Mexico, Turkey, South Africa
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
Baxalta now part of Shire

Completed

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

Hemophilia B

Korea, Republic of
University Hospital Inselspital, Berne

Withdrawn

Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars (KELOID)

Keloid | Hypertrophic Scars
rEVO Biologics
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

United States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
Triemli Hospital
University of Zurich

Completed

Blood Transfusion and Postoperative Outcome Before and After Implementing a Coagulation Management Algorithm (SONALG)

Coagulation Disorder, Blood

Switzerland
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
University of Pecs

Unknown

Haemostasis Management of Abdominal Aortic Procedures

Perioperative/Postoperative Complications | Abdominal Aortic Aneurism | Abdominal Aortic Rupture | Surgical Blood Loss
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Pennington Biomedical Research Center
National Institute of General Medical Sciences (NIGMS)

Completed

Addressing Health Disparities in African Americans - Exploring Sleep and Developing Interventions - 2 (HD-SLEEP2)

Sleep

United States
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Factor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann Thrombasthenia

United States, India, Italy, Russian Federation, Ukraine
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
University of Central Florida
University of Florida

Not yet recruiting

Biopsychosocial Contributors to Irritability in Individuals With Shoulder Pain

Shoulder Pain

United States
Dr. Servet Akar
Hacettepe University; Dokuz Eylul University

Unknown

Macro-scale Estimators of Covid-19's Worldwide Cases and Deaths

COVID19
CSL Behring

Completed

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Hemophilia B

Spain, Italy, France, Germany, Austria, Israel
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Haemophilia A

Poland, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Virginia Commonwealth University
HemoSonics LLC

Completed

Hemosonics- VCU Cardiac Surgery Clinical Study

Cardiopulmonary Bypass

United States
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Von Willebrand Disease

Poland, United Kingdom
American Thrombosis and Hemostasis Network
LFB USA, Inc.

Recruiting

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

United States
Swedish Orphan Biovitrum
Bioverativ Therapeutics Inc.

Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (ReITIrate)

Hemophilia A

Ireland, United Kingdom, Germany, United States, Canada, Slovenia, Sweden
Prothya Biosolutions

Completed

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Hemophilia B

Netherlands
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Haemophilia A

Poland
CSL Behring
Parexel

Completed

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Poland, Russian Federation, Ukraine
Istituto Clinico Humanitas

Recruiting

A Randomized Comparison of UnderwateR Versus Regular Coagulation in Endoscopic Submucosal DissectioN and Third Space Endoscopy

Gastrointestinal Diseases | Endoscopic Surgery

Italy

Search clinical trials for: coagulation-related factors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations